HitGen Inc. (688222)

Overview

HitGen Inc. is a pioneering entity in the drug discovery sector, focusing on the development of small molecules and nucleic acid drugs on a global scale, including China. Established in 2012 and headquartered in Chengdu, China, the company distinguishes itself by leveraging a range of cutting-edge technologies. These technologies encompass DNA-encoded library technology, fragment-based drug discovery, structure-based drug design, synthetic therapeutic oligonucleotide technology, and targeted protein degradation technology. HitGen's approach is deeply rooted in innovation, aiming to address complex challenges in various therapeutic areas such as oncology, immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious diseases, metabolic and cardiovascular diseases. Through its advanced technology platforms and extensive research and development efforts, HitGen has positioned itself as a key player in advancing drug discovery and development processes to meet the pressing needs of patients worldwide.

Products and Services

HG146 - A selective HDAC inhibitor targeted at multiple myeloma and solid tumors. This product exemplifies HitGen's commitment to advancing cancer treatment through innovative therapeutic strategies.

HG030 - A second-generation NTRK/ROS1 inhibitor in tablet form designed for the treatment of solid tumors. This development signifies HitGen's efforts in tackling cancers with specific genetic abnormalities.

HG 381 - An immune-oncology agonist aimed at enhancing the body's immune response against cancer. This product is part of HitGen's dedication to immuno-oncology, exploring new frontiers in cancer therapy.

HGT01 and HGT02 - These products focus on tumor immunology for cancer. They represent HitGen's venture into manipulating the immune system to recognize and eliminate cancer cells effectively.

HGT03 - A protein degrader, showcasing HitGen's engagement in targeted protein degradation technology, a novel approach in drug discovery that aims to degrade disease-causing proteins.

HGT04 - Focused on transcriptomics for cancer, this product highlights HitGen's interest in understanding gene expression patterns in cancer for the development of targeted therapies.

HGT05 - A kinase inhibitor for liver cancer, emphasizing the company's commitment to addressing specific types of cancer with precision medicine.

HGP0508 - A small molecule for the therapeutics of inflammation, representing HitGen's efforts in creating anti-inflammatory drugs to meet a broad range of health needs.

HGC245 - Another kinase inhibitor, this time for glaucoma, illustrating HitGen's venture into ophthalmology and its dedication to tackling eye diseases with innovative solutions.

HGP2142 - A TGF-ß1 specific siRNA drug for liver cancer. This nucleic acid drug pipeline entry showcases HitGen's commitment to advancing RNA interference (RNAi) technologies for cancer treatment.

HGN001 and HGN002 - These nucleic acid drugs are tailored for specific mutations of cancer targets, underlining HitGen's strategic focus on personalized medicine in oncology.

In addition to its product pipeline, HitGen offers a comprehensive suite of services covering every stage of drug discovery and development. These services include target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies, IND (Investigational New Drug) applications, clinical development, and integrated drug discovery. Through these services, HitGen supports its partners and clients across the pharmaceutical landscape in bringing new, effective drugs to market faster.